AR042300A1 - Mamiferos no humanos mutantes deficientes en receptores sigma y sus aplicaciones - Google Patents
Mamiferos no humanos mutantes deficientes en receptores sigma y sus aplicacionesInfo
- Publication number
- AR042300A1 AR042300A1 ARP030104478A ARP030104478A AR042300A1 AR 042300 A1 AR042300 A1 AR 042300A1 AR P030104478 A ARP030104478 A AR P030104478A AR P030104478 A ARP030104478 A AR P030104478A AR 042300 A1 AR042300 A1 AR 042300A1
- Authority
- AR
- Argentina
- Prior art keywords
- receptor
- sigma
- mutant
- deficient
- applications
- Prior art date
Links
- 230000002950 deficient Effects 0.000 title abstract 4
- 108010085082 sigma receptors Proteins 0.000 title abstract 4
- 241000124008 Mammalia Species 0.000 title 1
- 238000000034 method Methods 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 208000026139 Memory disease Diseases 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102100028662 Sigma intracellular receptor 2 Human genes 0.000 abstract 1
- 101710109012 Sigma intracellular receptor 2 Proteins 0.000 abstract 1
- 102100028656 Sigma non-opioid intracellular receptor 1 Human genes 0.000 abstract 1
- 101710104750 Sigma non-opioid intracellular receptor 1 Proteins 0.000 abstract 1
- 230000036592 analgesia Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000003412 degenerative effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 238000000099 in vitro assay Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 238000005462 in vivo assay Methods 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- 239000003176 neuroleptic agent Substances 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0356—Animal model for processes and diseases of the central nervous system, e.g. stress, learning, schizophrenia, pain, epilepsy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Environmental Sciences (AREA)
- Wood Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Animal Husbandry (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Biodiversity & Conservation Biology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
El genoma del mamífero no humano mutante, deficiente en un receptor Sigma endógeno, contiene una mutación que comprende una disrupción en un gen de un receptor Sigma endógeno, en donde dicha disrupción génica da lugar a una mutante que carece de niveles detectables de receptor Sigma endógeno. El mutante puede ser utilizado como animal control para ensayos in vivo, así como fuente de células que pueden ser utilizadas en ensayos in vitro. Los mutantes deficientes en el receptor Sigma-1 pueden utilizarse como modelos para estudiar in vivo desórdenes del sistema nervioso central, alteraciones de la memoria, condiciones de estrés y adición a drogas, procesos de analgesia y neuprotección. Los mutantes deficientes en el receptor Sigma-2 pueden utilizarse para estudiar herramientas, diagnósticos o terapéuticas, para combatir el cáncer y/o procesos degenerativos y/o para el diseno de compuestos capaces de prevenir, reducir o aliviar la patología secundaria asociada a la administración de agentes neurolépticos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200202815A ES2209650B2 (es) | 2002-12-09 | 2002-12-09 | Mamiferos no humanos mutantes deficientes en receptores sigma y sus aplicaciones. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR042300A1 true AR042300A1 (es) | 2005-06-15 |
Family
ID=32480022
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030104478A AR042300A1 (es) | 2002-12-09 | 2003-12-04 | Mamiferos no humanos mutantes deficientes en receptores sigma y sus aplicaciones |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8003847B2 (es) |
| EP (2) | EP1584232B1 (es) |
| JP (1) | JP4515915B2 (es) |
| AR (1) | AR042300A1 (es) |
| AT (1) | ATE360362T1 (es) |
| AU (1) | AU2003285369C1 (es) |
| CA (1) | CA2508697A1 (es) |
| CY (1) | CY1106675T1 (es) |
| DE (1) | DE60313499T2 (es) |
| DK (1) | DK1584232T3 (es) |
| ES (2) | ES2209650B2 (es) |
| HK (1) | HK1083987A1 (es) |
| NO (1) | NO20053367L (es) |
| PT (1) | PT1584232E (es) |
| WO (1) | WO2004052092A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2377530A3 (en) | 2005-10-21 | 2012-06-20 | Braincells, Inc. | Modulation of neurogenesis by PDE inhibition |
| EP2314289A1 (en) | 2005-10-31 | 2011-04-27 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| CA2651813A1 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| WO2007134077A2 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
| AU2007292848A1 (en) | 2006-09-08 | 2008-03-13 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5464764A (en) * | 1989-08-22 | 1995-11-07 | University Of Utah Research Foundation | Positive-negative selection methods and vectors |
| WO1998020112A1 (en) | 1996-11-07 | 1998-05-14 | The Wistar Institute Of Anatomy And Biology | Sparc-deficient transgenic mice |
| US6194633B1 (en) | 1998-01-26 | 2001-02-27 | University Of Iowa Research Foundation | Non-human animal having a functionally disrupted SLP-76 gene |
| US6207876B1 (en) | 1998-04-28 | 2001-03-27 | Board Of Regents, The University Of Texas System | Adenosine deaminase deficient transgenic mice and methods for the use thereof |
| US6252132B1 (en) | 1998-11-02 | 2001-06-26 | Institut Pasteur | Mutant mouse containing a knockout mutation in DNA encoding an endogenous alpha 4 subunit of nicotinic acetylcholine receptor |
| US6245965B1 (en) | 1999-01-29 | 2001-06-12 | St. Jude Children's Research Hospital | Knockout mice and cells that lack p19INK4d and p27KIP1 activity and methods of use thereof |
| US6245963B1 (en) | 1999-05-28 | 2001-06-12 | Academia Sinica | Knockout-transgenic mouse model of spinal muscular atrophy |
| JP4470077B2 (ja) * | 1999-11-16 | 2010-06-02 | 和男 鈴木 | 好中球走化性因子ｌｅｃｔ２遺伝子の機能が欠損したマウス |
-
2002
- 2002-12-09 ES ES200202815A patent/ES2209650B2/es not_active Expired - Fee Related
-
2003
- 2003-12-04 AR ARP030104478A patent/AR042300A1/es not_active Application Discontinuation
- 2003-12-09 AT AT03778357T patent/ATE360362T1/de active
- 2003-12-09 AU AU2003285369A patent/AU2003285369C1/en not_active Ceased
- 2003-12-09 US US10/731,379 patent/US8003847B2/en not_active Expired - Fee Related
- 2003-12-09 DE DE60313499T patent/DE60313499T2/de not_active Expired - Lifetime
- 2003-12-09 EP EP03778357A patent/EP1584232B1/en not_active Expired - Lifetime
- 2003-12-09 CA CA002508697A patent/CA2508697A1/en not_active Abandoned
- 2003-12-09 ES ES03778357T patent/ES2286484T3/es not_active Expired - Lifetime
- 2003-12-09 DK DK03778357T patent/DK1584232T3/da active
- 2003-12-09 EP EP06120550A patent/EP1752540A3/en not_active Withdrawn
- 2003-12-09 JP JP2004558125A patent/JP4515915B2/ja not_active Expired - Fee Related
- 2003-12-09 WO PCT/ES2003/000624 patent/WO2004052092A1/es active IP Right Grant
- 2003-12-09 PT PT03778357T patent/PT1584232E/pt unknown
-
2005
- 2005-07-11 NO NO20053367A patent/NO20053367L/no not_active Application Discontinuation
-
2006
- 2006-04-11 HK HK06104406A patent/HK1083987A1/xx not_active IP Right Cessation
-
2007
- 2007-06-25 CY CY20071100839T patent/CY1106675T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO20053367D0 (no) | 2005-07-11 |
| DE60313499T2 (de) | 2008-01-03 |
| EP1584232A1 (en) | 2005-10-12 |
| ES2209650A1 (es) | 2004-06-16 |
| NO20053367L (no) | 2005-07-11 |
| AU2003285369B2 (en) | 2009-09-10 |
| US8003847B2 (en) | 2011-08-23 |
| JP2006508673A (ja) | 2006-03-16 |
| JP4515915B2 (ja) | 2010-08-04 |
| EP1584232B1 (en) | 2007-04-25 |
| DE60313499D1 (de) | 2007-06-06 |
| ATE360362T1 (de) | 2007-05-15 |
| ES2209650B2 (es) | 2006-11-01 |
| WO2004052092A1 (es) | 2004-06-24 |
| DK1584232T3 (da) | 2007-07-30 |
| HK1083987A1 (en) | 2006-07-21 |
| EP1752540A2 (en) | 2007-02-14 |
| US20050132429A1 (en) | 2005-06-16 |
| EP1752540A3 (en) | 2007-11-21 |
| AU2003285369C1 (en) | 2010-02-18 |
| AU2003285369A1 (en) | 2004-06-30 |
| CA2508697A1 (en) | 2004-06-24 |
| CY1106675T1 (el) | 2012-05-23 |
| ES2286484T3 (es) | 2007-12-01 |
| PT1584232E (pt) | 2007-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rapanelli et al. | Targeted interneuron depletion in the dorsal striatum produces autism-like behavioral abnormalities in male but not female mice | |
| Costa et al. | Prospects for improving brain function in individuals with Down syndrome | |
| de Bartolomeis et al. | Serotonin–glutamate and serotonin–dopamine reciprocal interactions as putative molecular targets for novel antipsychotic treatments: from receptor heterodimers to postsynaptic scaffolding and effector proteins | |
| CY1106675T1 (el) | Μεταλλαγμενα, μη ανθρωπινα θηλαστικα με ελλειψη σιγμα υποδοχεα και εφαρμογες αυτων | |
| Wadenberg | Conditioned avoidance response in the development of new antipsychotics | |
| Bymaster et al. | Role of the cholinergic muscarinic system in bipolar disorder and related mechanism of action of antipsychotic agents | |
| Hao et al. | L-Stepholidine rescues memory deficit and synaptic plasticity in models of Alzheimer’s disease via activating dopamine D1 receptor/PKA signaling pathway | |
| HN2009000018A (es) | Inhibidores de tirosina quinasa | |
| BRPI0607307A2 (pt) | compostos e composições como inibidores de proteìna cinase | |
| Nishiyori et al. | Absence of morphine analgesia and its underlying descending serotonergic activation in an experimental mouse model of fibromyalgia | |
| Baroja-Mazo et al. | Modulating P2X7 receptor signaling during rheumatoid arthritis: new therapeutic approaches for bisphosphonates | |
| BRPI0518722A2 (pt) | mÉtodo de formaÇço de microbolhas de vidro, e, produto bruto | |
| Nackenoff et al. | Essential contributions of serotonin transporter inhibition to the acute and chronic actions of fluoxetine and citalopram in the SERT Met172 mouse | |
| AR063158A1 (es) | Asenapina amorfa,p rocesos para prepararla, composiciones farmaceuticas solidas que la contienen y su uso para tratar trastornos del sistema nervioso central. | |
| Wang et al. | The involvement of DARPP-32 in the pathophysiology of schizophrenia | |
| Miyazaki et al. | Role of convergent activation of glutamatergic and dopaminergic systems in the nucleus accumbens in the development of methamphetamine psychosis and dependence | |
| BR112017022779A2 (pt) | métodos para detectar uma mutação de deleção em marco (indel) no éxon 9 do gene da calreticulina, para diagnosticar uma doença hematopoiética em um paciente, para determinar a probabilidade de um paciente desenvolver uma mutação em um gene de via jak-stat para determinar o prognóstico de um paciente com uma doença mieloproliferativa, kit, e, sonda ou iniciador oligonucleotídico | |
| CY1114479T1 (el) | Φαρμακολογικη επικουρικη αγωγη σε συνδυασμο με διηθητικη χειρουργικη επεμβαση γλαυκωματος | |
| Hamann | Bilingual development and language assessment | |
| BRPI0414049A (pt) | compostos e composições como inibidores de proteìna cinase | |
| Miranda et al. | The preclinical discovery and development of quetiapine for the treatment of mania and depression | |
| Ujvári et al. | Neurodegeneration in the centrally-projecting Edinger–Westphal nucleus contributes to the non-motor symptoms of Parkinson’s disease in the rat | |
| Perrine et al. | Cocaine regulates protein kinase B and glycogen synthase kinase‐3 activity in selective regions of rat brain | |
| Cowen et al. | New approaches to treating resistant depression | |
| Gautam et al. | M1–M3 muscarinic acetylcholine receptor-deficient mice |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |